Tirzepatide vs Tesamorelin
A comprehensive, data-driven comparison of Tirzepatide (Mounjaro) and Tesamorelin (Egrifta). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | Tirzepatide Mounjaro, Zepbound | Tesamorelin Egrifta, TH9507 |
|---|---|---|
| FDA Status | FDA Approved | FDA Approved |
| Category | Weight Loss | Growth Hormone |
| Primary Use | Type 2 diabetes, chronic weight management, and obstructive sleep apnea | HIV-associated lipodystrophy |
| Weight Loss % | 22.5% | N/A |
| Monthly Cost | $1,100 - $1,100/mo | $200 - $1,500/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 15mg weekly (max dose) | 2mg daily |
| Frequency | Weekly | Daily |
| Mechanism | Dual GIP/GLP-1 receptor agonist that enhances insulin secretion, reduces glucagon, slows gastric emptying, and decreases appetite | Synthetic GHRH analog that reduces visceral adipose tissue by stimulating growth hormone production |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | High | High |
| Clinical Trial Phase | Approved | Approved |
Key Differences
- 1Tirzepatide has clinical weight loss data (22.5%), while Tesamorelin is not primarily indicated for weight loss.
- 2Tesamorelin is generally more affordable ($200 - $1,500/mo) compared to Tirzepatide ($1,100 - $1,100/mo).
- 3Tirzepatide is dosed weekly, while Tesamorelin is daily.
- 4They belong to different categories: Tirzepatide (Weight Loss) vs Tesamorelin (Growth Hormone).
Which Is Better For...
Tesamorelin
More budget-friendly option with lower monthly costs
Tirzepatide
More convenient dosing schedule (weekly)
Tesamorelin
Fewer commonly reported side effects
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| Tirzepatide | $1,100 - $1,100/mo | FDA Approved | Eli Lilly |
| Tesamorelin | $200 - $1,500/mo | FDA Approved | Theratechnologies |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
Tirzepatide works via Dual GIP/GLP-1 receptor agonist that enhances insulin secretion, reduces glucagon, slows gastric. Tesamorelin works via Synthetic GHRH analog that reduces visceral adipose tissue by stimulating growth hormone. They differ in FDA approval status, efficacy data, and cost.
Tirzepatide has demonstrated 22.5% average weight loss in clinical trials. Tesamorelin is not primarily used for weight loss.
Tirzepatide typically costs $1,100 - $1,100/mo, while Tesamorelin costs $200 - $1,500/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
Tirzepatide is FDA-approved. Tesamorelin is FDA-approved. FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of Tirzepatide include Nausea, Diarrhea, Decreased appetite. Common side effects of Tesamorelin include Injection site reactions, Arthralgia, Peripheral edema. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
Tirzepatide is a dual-action peptide approved by the FDA as Mounjaro for type 2 diabetes and Zepbound for weight management. In December 2024, Zepbound became the first and only medication approved fo...
View Full Tirzepatide GuideTesamorelin is an FDA-approved synthetic growth hormone releasing hormone analog specifically indicated for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. A new weekly reco...
View Full Tesamorelin GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between Tirzepatide and Tesamorelin should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.